Cancer-associated fibroblast-derived lactate drives cholangiocarcinoma progression via H4K12la-mediated oxidative phosphorylation activation
Background: Cholangiocarcinoma (CCA) is a highly aggressive malignancy, and chemoresistance is a major cause of poor prognosis. This study aimed to elucidate the molecular mechanisms driving CCA progression from a tumor microenvironment perspective and to develop novel strategies to enhance chemosensitivity. Methods: Single-cell RNA-seq, untargeted metabolomics, and proteomics were used to identify the source of lactate in the CCA microenvironment and the metabolic reprogramming of cancer-associated fibroblasts (CAFs). To evaluate the impact of CAF-derived lactate on prognosis, we performed AAV-mediated MCT4 knockdown followed by hydrodynamic injection to induce a CCA model. Co-culture models were combined with genome-wide CUT&Tag, MeRIP-seq, and RIP-seq to resolve epigenetic and post-transcriptional regulatory mechanisms. The antitumor effects of 7ACC1 (a small molecule reported to inhibit lactate uptake), alone or in combination with gemcitabine, were assessed in subcutaneous and orthotopic liver xenograft models. Results: CAFs undergo glycolytic reprogramming, resulting in aberrant lactate accumulation. Mechanistically, CAF-derived lactate induces H4K12 lactylation (H4K12la) in CCA cells, which in turn activates the IGF2BP3/ATF3 axis to upregulate oxidative phosphorylation and promote tumor progression. The lactate shuttle inhibitor 7ACC1, combined with gemcitabine, exerts promising antitumor effects. Clinically, high levels of MCT4, α SMA, and H4K12la are associated with poor prognosis in patients with CCA. Conclusions: These findings reveal that CAFs drive CCA progression via lactate-induced H4K12la, which activates the IGF2BP3/ATF3 axis. The findings provide a preclinical rationale for further evaluation of lactate-uptake-targeting strategies in combination with gemcitabine for CCA.
Authors
- Yananlan Chen
- Shenye Shao
- Kai Cao
- Shuochen Liu
- Xiangcheng Li
- Xiao Xu
- Changxian Li
- Ziyang Wang
- Ji Cui
- Jiawei Zhang
Institutions
- Nanjing University of Chinese Medicine (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Jiangsu Province Hospital (CN)
- Wuxi People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3350/cmh.2026.0591
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00